In the battle for Guidant, Boston Scientific's latest bid -- $80 per share tendered Tuesday morning -- trumps J&J's $71 per share. Much of the difference between the two bids comes from Abbott Laboratories, which is paying Boston Scientific about $6.5 billion at the close of the merger -- if it succeeds. Abbott has been a key player on both sides of the bidding war, gaining momentum each time a counterpunch is thrown. And no matter who wins Guidant, Abbott stands to gain valuable assets.
January 19, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
If Boston Scientific Corp. wins its battle royal with Johnson & Johnson over Guidant Corp., the company will owe a big debt to Abbott Laboratories, and not just a debt of gratitude.
Guidant said Tuesday, it favors Boston Scientific’s latest bid, $80 per share tendered Tuesday morning. That trumps J&J’s $71 per share. The declaration is not the same as acceptance: It has until Jan. 25 to consider the bid.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
McCarter & English, LLP, a well established and growing law firm, is actively seeking a talented and driven associate having 2-5 years o...
McCarter & English, LLP is actively seeking a corporate associate for its office located in Wilmington, DE or Philadelphia, PA. Candidat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
